A wholly-owned subsidiary of HYTN Innovations Inc.,
The European Psychiatric Association (EPA) is joining the Psychedelic Access and Research European Alliance (PAREA) as a full member.
The first patient has now been dosed in IntelGEnx and atai Life Sciences’ Phase 1 clinical trial to investigate buccal VLS-01 – a buccal film containing...
Palo Santo has announced the closing of its USD$50m (~£134.10m) fund which will go towards a diverse portfolio of businesses developing innovative psychedelic medicines and therapies.
Biomind Labs has confirmed that it has had a Pre-Investigational New Drug (Pre-IND) meeting granted by the U.S.
In a groundbreaking move for Canada’s regulatory developments around psychedelics, Alberta has announced it will be introducing quality standards into its Mental Health Services Protection Act...
Cybin has entered into an agreement with Mindset Pharma to acquire an exclusive license to an extensive, targeted class of tryptamine-based molecules.
University of Cincinnati postdoctoral researcher Neşe Devenot has stated that the field of psychedelics is fraught with ethical concerns and financial interests.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided Mindset Pharma with Scientific Advice on a range of points to finalise its MSP-1014 clicnial...
A new study by Johns Hopkins Medicine researchers compared psychedelic experiences with near-death experiences that were not drug-related, finding notable similarities in people’s attitudes toward death.